Latest "Galectin Therapeutics" News Stories

02:31 EDT 30th May 2015 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 52

Relevant

Galectin Therapeutics to Present at LD Micro Invitational Conference

NORCROSS, Ga., May 28, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James Czirr, executive chairman, will present a corporate overview and update at the LD Micro Invitational Conference on June 2, 2015, at 4:00 p.m. Pacific time. The conference is being held at t...

Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02

Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patients with cirrhosis, and a smaller trial to confirm the safety and therapeutic effect on NASH patients with advanced fibrosis Both studies to begin in the second quarter of 2015 Company to submit a Special Protocol Assessment to the FDA by the end of the month NORCROSS, Ga., Feb. 24...

Galectin Therapeutics to Present at the 27th Annual ROTH Conference

NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 9, 2015 at 11:00 a.m. Pacific time. The conference is bei...

BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test

WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorporates data generated from a study in which levels of the pr...

Galectin Therapeutics, Inc. - Product Pipeline Review - 2014

Recently added to the BioPortfolio report store, Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 is a new report from Global Markets Direct published on 2014-12-14. This 40-page report is available in PDF from $1500. Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Galectin Therapeutics, Inc. - Product Pipeline Review - 2014’, prov...

Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference

NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST...

The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.

Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update

NORCROSS, Ga., March 18, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the year ended December 31, 2014. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commiss...

Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders

NORCROSS, Ga., May 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will webcast a corporate update at 9:45 A.M. ET on Thursday, May 21, 2015, immediately following the business portion of the Company's Annual Meeting of Stockholders. Additionally, Peter Traber, M.D., president, chief executive officer and chief medical officer will discuss the Company's pipeline of galectin inhib...

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential

Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium

NORCROSS, Ga., March 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that Peter G. Traber, M.D., president, chief executive officer and chief medical officer, delivered an invited presentation of the Company's research with lead compound GR-MD-02 in non-alcoholic steatohep...

Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA

NORCROSS, Ga., March 12, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it has engaged the contract research organization Pharmaceutical Product Development, LLC (PPD) to conduct the Phase 2 trial with GR-MD-02 for the treatment of liver fibrosis and resultant portal hyperten...

The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal–fetal interface in early pregnancy

Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program

NORCROSS, Ga., May 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2015. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange C...

Targeted inhibition of galectin 1 by thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats

Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

NORCROSS, Ga., May 14, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that in an open-label Phase 1 study with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observ...

Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis

NORCROSS, Ga., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that final results from its Phase 1 trial show that GR-MD-02 had an effect on a serum biomarker (as assessed by FibroTest®) and liver stiffness (as assessed by FibroScan®) that suggest a potential for the...

Image of the Day: Snail Blood

The galectin proteins (green) expressed in snail hemocytes—which are equivalent to human white blood cells—bind to the parasitic worm that causes schistosomiasis in people.

La Jolla begins Phase IIb trial of GCS-100 to treat advanced CKD

US-based biotechnology firm La Jolla Pharmaceutical has started a Phase IIb clinical trial of its galectin-3 inhibitor, GCS-100, to treat advanced chronic kidney disease (CKD) caused by diabetes.

Probably Relevant

BG Medicine, Inc. (BGMD) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, BG Medicine, Inc. (BGMD) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2014-11-20. This 25-page report is available in PDF from $300. Summary BG Medicine, Inc. (BGM) is a life science company. The company discovers, develops and delivers diagnostic solutions to aid in the clinical management of heart f...

La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview a...

BMS extends fibrosis research with Calibr collaboration

Bristol-Myers Squibb has unveiled a new research collaboration in the area of anti-fibrotic therapies, an area tipped for huge market growth.The US pharma company is to work with the California Institute for Biomedical Research (Calibr) on developing...

La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its Phase 2b clinical trial of GCS-100 for the treatment of advanced

Patent Awarded for New Anti-Cancer Botanical Combination

SANTA ROSA, Calif., Feb. 3, 2015 /PRNewswire/ -- Dr. Isaac Eliaz, a widely respected integrative medical doctor and researcher, has been awarded a USA patent from the U.S. Patent and Trademark Office for his innovative combination of modified citrus pectin (MCP) and honokiol extract from magnolia tree bark. This combination has broad, multi-targeted potential to help stop the growth and sprea...

Modified Citrus Pectin Enhances Radiation Therapy in Prostate Cancer Treatment

PHILADELPHIA, April 22, 2015 /PRNewswire/ -- Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells. Results were presented today at the American Association for Cancer Research (AACR) Annual Me...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks